TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06925737: A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 1440 pts

Competing Trials Overlap

11 Active Trials

Excess Burn Exposure

$787,248

Rescue Site Savings

+$524,832

Unlock Full NCT06925737 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06925737 Rescue Dossier →